Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 176

Similar articles for PubMed (Select 23525453)

1.

Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.

Du N, Li X, Li F, Zhao H, Fan Z, Ma J, Fu Y, Kang H.

Oncol Rep. 2013 Jun;29(6):2332-40. doi: 10.3892/or.2013.2349. Epub 2013 Mar 15.

PMID:
23525453
2.

Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.

Kitamura K, Kubota K, Ando M, Takahashi S, Nishijima N, Sugano T, Toyokawa M, Miwa K, Kosaihira S, Noro R, Minegishi Y, Seike M, Yoshimura A, Gemma A.

Cancer Chemother Pharmacol. 2013 Feb;71(2):457-61. doi: 10.1007/s00280-012-2026-4. Epub 2012 Nov 21.

PMID:
23178954
3.

Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.

Tamiya M, Tamiya A, Yamadori T, Nakao K, Asami K, Yasue T, Otsuka T, Shiroyama T, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Kawase I, Hirashima T.

Med Oncol. 2013;30(3):676. doi: 10.1007/s12032-013-0676-7. Epub 2013 Aug 8.

PMID:
23925664
4.

Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer.

Tohda Y, Iwanaga T, Takada M, Yana T, Kawahara M, Negoro S, Okishio K, Kudoh S, Fukuoka M, Furuse K.

Chemotherapy. 1999 May-Jun;45(3):197-204.

PMID:
10224342
5.

Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non-small cell lung cancer.

Ishida A, Miyazawa T, Miyazu Y, Iwamoto Y, Zaima M, Kanoh K, Sumiyoshi H, Doi M.

Respirology. 2006 Jan;11(1):90-7.

PMID:
16423208
6.

First-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer : analysis of the Italian patients enrolled in the SAiL study.

Bearz A, Passalacqua R, Alabiso O, Cinieri S, Gridelli C, Cravesana C, Crinò L.

Clin Drug Investig. 2012 Nov;32(11):755-60. doi: 10.1007/s40261-012-0001-9.

PMID:
23018280
7.

Bevacizumab in non-small cell lung cancer.

Di Costanzo F, Mazzoni F, Micol Mela M, Antonuzzo L, Checcacci D, Saggese M, Di Costanzo F.

Drugs. 2008;68(6):737-46. Review.

PMID:
18416583
8.

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C.

J Clin Oncol. 2009 Mar 10;27(8):1227-34. doi: 10.1200/JCO.2007.14.5466. Epub 2009 Feb 2. Erratum in: J Clin Oncol. 2009 May 10;27(14):2415.

9.
10.

Intrapleural chemo- and hyperthermotherapies for malignant pleural effusion: a randomized prospective study.

Chen WJ, Yuan SF, Yan QY, Xiong JP, Wang SM, Zheng WE, Zhang W, Sun HY, Chen H, Wu LL.

Cancer Invest. 2012 Feb;30(2):126-30. doi: 10.3109/07357907.2011.633292. Epub 2011 Dec 7.

PMID:
22148972
11.

Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.

Ren S, Terman DS, Bohach G, Silvers A, Hansen C, Colt H, Sahn SA.

Chest. 2004 Nov;126(5):1529-39. Erratum in: Chest. 2011 Sep;140(3):835.

PMID:
15539723
12.

Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.

Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, Rotundo MS, Tassone P, Sperlongano P, Abbruzzese A, Caraglia M, Tagliaferri P, Francini G.

Cancer Biol Ther. 2010 May 1;9(9):685-93.

PMID:
20697196
13.

Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial.

Mok TS, Hsia TC, Tsai CM, Tsang K, Chang GC, Chang JW, Sirisinha T, Sriuranpong V, Thongprasert S, Chua DT, Moore N, Manegold C.

Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:4-12. doi: 10.1111/j.1743-7563.2011.01397.x. Erratum in: Asia Pac J Clin Oncol. 2011 Sep;7(3):321. Thitiya, Sirisinha [corrected to Sirisinha, Thitiya].

PMID:
21585703
14.

Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial.

Seto T, Ushijima S, Yamamoto H, Ito K, Araki J, Inoue Y, Semba H, Ichinose Y; Thoracic Oncology Group.

Br J Cancer. 2006 Sep 18;95(6):717-21. Epub 2006 Aug 29.

15.

First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients.

Leon L, Vázquez S, Gracia JM, Casal J, Lazaro M, Firvida JL, Amenedo M, Santome L, Macia S.

Expert Opin Pharmacother. 2012 Jul;13(10):1389-96. doi: 10.1517/14656566.2012.693165. Epub 2012 May 25.

PMID:
22630129
16.

Clinical observation on the efficacy of Xiaoshui decoction combined with intrapleural perfusion of cisplatin in treating malignant pleural effusion.

SHI Z, HE QY, HUA BJ.

Chin J Integr Med. 2008 Dec;14(4):257-61. doi: 10.1007/s11655-008-0257-3. Epub 2008 Dec 12.

PMID:
19082796
17.

Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy.

An SJ, Huang YS, Chen ZH, Su J, Yang Y, Chen JG, Yan HH, Lin QX, Yang JJ, Yang XN, Zhou Q, Zhang XC, Wu YL.

Med Oncol. 2012 Jun;29(2):627-32. doi: 10.1007/s12032-011-9924-x. Epub 2011 Apr 3.

PMID:
21461966
18.

Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes.

Chang GC, Ahn MJ, Wright E, Kim HT, Kim JH, Kang JH, Kim SW, Sherman S, Walzer S.

Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:34-40. doi: 10.1111/j.1743-7563.2011.01400.x.

PMID:
21585706
19.

Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial.

Rusch VW, Figlin R, Godwin D, Piantadosi S.

J Clin Oncol. 1991 Feb;9(2):313-9.

PMID:
1988578
20.

Modified intrapleural cisplatin treatment for lung cancer with positive pleural lavage cytology or malignant effusion.

Muraoka M, Oka T, Akamine S, Tagawa T, Morinaga M, Inoue M, Yamayoshi T, Hashizume S, Matsumoto K, Hayashi T, Nagayasu T.

J Surg Oncol. 2006 Mar 15;93(4):323-9.

PMID:
16496367
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk